Literature DB >> 30848956

Lynch Syndrome: From Screening to Diagnosis to Treatment in the Era of Modern Molecular Oncology.

Stacey A Cohen1,2, Colin C Pritchard3, Gail P Jarvik4,5.   

Abstract

Lynch syndrome is a hereditary cancer predisposition syndrome caused by germline alterations in the mismatch repair genes and is the most common etiology of hereditary colorectal cancer. While Lynch syndrome was initially defined by the clinical Amsterdam criteria, these criteria lack the sensitivity needed for clinical utility. This review covers the evolution of screening for Lynch syndrome from the use of tumor microsatellite instability and/or somatic alterations in mismatch repair protein expression by immunohistochemistry to the newest methods using next-generation sequencing. Additionally, it discusses the clinical implications of the diagnosis of Lynch syndrome as it affects cancer therapeutics and the role of screening in noncolorectal Lynch-associated cancers. As molecular oncology continues to evolve, it is crucial to remain current on the increasing complexity of Lynch syndrome diagnostics and treatment options.

Entities:  

Keywords:  colorectal cancer; microsatellite instability; mismatch repair

Mesh:

Substances:

Year:  2019        PMID: 30848956     DOI: 10.1146/annurev-genom-083118-015406

Source DB:  PubMed          Journal:  Annu Rev Genomics Hum Genet        ISSN: 1527-8204            Impact factor:   8.929


  15 in total

1.  Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors.

Authors:  Vladimir Roudko; Cansu Cimen Bozkus; Theofano Orfanelli; Christopher B McClain; Caitlin Carr; Timothy O'Donnell; Lauren Chakraborty; Robert Samstein; Kuan-Lin Huang; Stephanie V Blank; Benjamin Greenbaum; Nina Bhardwaj
Journal:  Cell       Date:  2020-11-30       Impact factor: 41.582

2.  Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report-Usage of Immune Checkpoint Inhibition in CMMRD.

Authors:  Rebekah Rittberg; Craig Harlos; Heidi Rothenmund; Anirban Das; Uri Tabori; Namita Sinha; Harminder Singh; Bernie Chodirker; Christina A Kim
Journal:  Curr Oncol       Date:  2021-02-01       Impact factor: 3.677

Review 3.  Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.

Authors:  Rodolfo Montironi; Alessia Cimadamore; Antonio Lopez-Beltran; Marina Scarpelli; Gaetano Aurilio; Matteo Santoni; Francesco Massari; Liang Cheng
Journal:  Cells       Date:  2020-04-25       Impact factor: 6.600

4.  A rare large duplication of MLH1 identified in Lynch syndrome.

Authors:  Abhishek Kumar; Nagarajan Paramasivam; Kari Hemminki; Asta Försti; Obul Reddy Bandapalli; Matthias Schlesner; Tianhui Chen; Rolf Sijmons; Dagmara Dymerska; Katarzyna Golebiewska; Magdalena Kuswik; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2021-01-19       Impact factor: 2.857

Review 5.  Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines.

Authors:  Vladimir Roudko; Cansu Cimen Bozkus; Benjamin Greenbaum; Aimee Lucas; Robert Samstein; Nina Bhardwaj
Journal:  Front Immunol       Date:  2021-09-24       Impact factor: 7.561

6.  Prevalence of cancer susceptibility variants in patients with multiple Lynch syndrome related cancers.

Authors:  Yoon Young Choi; Su-Jin Shin; Jae Eun Lee; Lisa Madlensky; Seung-Tae Lee; Ji Soo Park; Jeong-Hyeon Jo; Hyunki Kim; Daniela Nachmanson; Xiaojun Xu; Sung Hoon Noh; Jae-Ho Cheong; Olivier Harismendy
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

7.  Assessment of Expression of Homeobox A5 in Endometrial Cancer on the mRNA and Protein Level.

Authors:  Konrad Dziobek; Marcin Oplawski; Nikola Zmarzły; Beniamin O Gabarek; Robert Kiełbasiński; Kamil Kiełbasiński; Przemysław Kieszkowski; Karol Talkowski; Dariusz Boroń
Journal:  Curr Pharm Biotechnol       Date:  2020       Impact factor: 2.837

8.  Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay.

Authors:  Sarabjot Pabla; Jonathan Andreas; Felicia L Lenzo; Blake Burgher; Jacob Hagen; Vincent Giamo; Mary K Nesline; Yirong Wang; Mark Gardner; Jeffrey M Conroy; Antonios Papanicolau-Sengos; Carl Morrison; Sean T Glenn
Journal:  Oncotarget       Date:  2019-08-27

9.  Case Report and Literature Review: Diagnosis, Tailored Genetic Counseling and Cancer Prevention for a Locally Advanced dMMR/MSI-H/TMB-H Lung Cancer Patient With Concurrent Lynch Syndrome Mediated by a Rare PMS2 Splicing Variant (c.1144+1G>A).

Authors:  Quanli Han; Si Liu; Zhi Cui; Qi Wang; Tonghui Ma; Liwen Jiang; Xiaomo Li; Guanghai Dai
Journal:  Front Genet       Date:  2022-01-18       Impact factor: 4.599

10.  WRN Germline Mutation Is the Likely Inherited Etiology of Various Cancer Types in One Iranian Family.

Authors:  Mahnaz Norouzi; Mohammad Shafiei; Zeinab Abdollahi; Paniz Miar; Hamid Galehdari; Mohammad Hasan Emami; Mehrdad Zeinalian; Mohammad Amin Tabatabaiefar
Journal:  Front Oncol       Date:  2021-06-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.